Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 16/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 16/20 | 0.58 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201278 | 1.00 | ITGB1 (0.58) | ITGB1ITGA4ITGB7CNR1 | |
| SCHEMBL3904073 | 0.92 | ITGB1 (0.67) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3904078 | 0.92 | ITGB1 (0.67) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2988722 | 0.91 | ITGB1 (0.66) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2988718 | 0.91 | ITGB1 (0.66) | ITGB1ITGA4ITGB7 | |
| SCHEMBL7237244 | 0.85 | HCRTR1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL7237249 | 0.85 | HCRTR1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL7226993 | 0.81 | ITGB1 (0.50) | ITGB1ITGA4ITGB7CNR1 | |
| SCHEMBL7226992 | 0.81 | ITGB1 (0.50) | ITGB1ITGA4ITGB7CNR1 | |
| SCHEMBL7228012 | 0.81 | ITGB1 (0.50) | ITGB1ITGA4ITGB7CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | SAINT LOUIS UNIVERSITY | 2019-10-31 | — | — | US | disclosed |
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | SAINT LOUIS UNIVERSITY | 2019-10-31 | — | — | US | disclosed |
| EP-1389200-A4 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-6943180-B2 | Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| US-6734311-B2 | ANTIINFLAMMATORY AGENTS; ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2004-05-11 | — | — | US | disclosed |
| EP-1389200-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | MERCK & CO., INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002074761-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2000071572-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | CXCL12, CXCR4, SDF4 | ITGB1 8/4885ITGA4 7/4885ITGB7 16/4885 |
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | VCAM1, CD4, ICAM1 | ITGB1 9/4885ITGA4 5/4885ITGB7 14/4885 |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ICAM1 | ITGB1 28/4885ITGA4 4/4885ITGB7 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.